New drug cocktail targets tough lung cancer

NCT ID NCT07283198

Not yet recruiting Disease control Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests JSKN033, a combination of two drugs (a HER2-targeted antibody-drug conjugate and a PD-L1 inhibitor), in 160 people with advanced non-small cell lung cancer that cannot be cured. The study will first find the best dose, then expand to see how well it shrinks tumors and controls the disease. Researchers are also monitoring side effects closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JSKN033 (a combination of a HER2-targeted antibody-drug conjugate and a PD-L1 inhibitor)
What this could lead to: If successful, this could provide a new treatment option for people with advanced non-small cell lung cancer who have limited choices.
What could go wrong: This is an early Phase 2 trial with a small number of participants, so results may not apply to everyone. Side effects from the drug combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.